These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 25047655

  • 1. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [Abstract] [Full Text] [Related]

  • 2. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW.
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [Abstract] [Full Text] [Related]

  • 3. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
    Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW.
    Oncotarget; 2014 Jul 15; 5(13):4909-19. PubMed ID: 24952874
    [Abstract] [Full Text] [Related]

  • 4. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb 15; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 5. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF.
    Breast Cancer Res Treat; 2014 Jul 15; 146(1):71-84. PubMed ID: 24903225
    [Abstract] [Full Text] [Related]

  • 6. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 7. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 28; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 9. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF.
    Breast Cancer Res; 2013 Feb 28; 15(4):R63. PubMed ID: 23938089
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.
    Hepatology; 2014 Jan 28; 59(1):190-201. PubMed ID: 23908138
    [Abstract] [Full Text] [Related]

  • 11. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 28; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 12. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.
    Cell Death Dis; 2013 Feb 07; 4(2):e485. PubMed ID: 23392173
    [Abstract] [Full Text] [Related]

  • 13. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT, Shiau CW, Li YS, Chen YL, Chu PY, Huang JW, Hsu CY, Hsu YC, Chen PJ, Chen KF.
    Mol Cancer Ther; 2014 Jan 07; 13(1):27-36. PubMed ID: 24275147
    [Abstract] [Full Text] [Related]

  • 14. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.
    J Hepatol; 2011 Nov 07; 55(5):1041-8. PubMed ID: 21354226
    [Abstract] [Full Text] [Related]

  • 15. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW.
    Cancer Lett; 2012 Aug 01; 321(1):27-35. PubMed ID: 22465052
    [Abstract] [Full Text] [Related]

  • 16. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
    Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, Kudo M.
    Cancer Sci; 2017 Oct 01; 108(10):1996-2003. PubMed ID: 28777492
    [Abstract] [Full Text] [Related]

  • 17. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr 01; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY, Su JC, Huang TT, Chu PY, Huang CT, Wang WL, Lee CH, Lau KY, Tsai WC, Yang HP, Shiau CW, Tseng LM, Chen KF.
    Mol Oncol; 2017 Mar 01; 11(3):266-279. PubMed ID: 28084011
    [Abstract] [Full Text] [Related]

  • 19. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.
    Mol Cancer; 2014 Jan 13; 13():7. PubMed ID: 24418169
    [Abstract] [Full Text] [Related]

  • 20. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY, Chen KF, Chao TI, Chu PY, Huang CT, Huang TT, Yang HP, Wang WL, Lee CH, Lau KY, Tsai WC, Su JC, Wu CY, Chen MH, Shiau CW, Tseng LM.
    J Mol Med (Berl); 2017 Sep 13; 95(9):965-975. PubMed ID: 28578456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.